Biora Therapeutics, Inc. (PROG) News & Overview - Discounting Cash Flows
PROG
Biora Therapeutics, Inc.
PROG (NASDAQ)

PROG's Business Model

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.progenity.com
CEO (Chief Executive Officer) Harry Stylli
Number of Employees
IPO date June 19, 2020

PROG Latest News

Contact
CountryUS
Address4330 La Jolla Village Drive
CitySan Diego
StateCA
Phone855-293-2639
Zip Code92122
Other Identifiers
CIK0001580063
ISINUS74319F1075
CUSIP74319F107
Open0.9005
Previous Close0.9163
Volume2.78 Mil.
Average Volume6.37 Mil.
Day’s Range0.84 – 0.92
52 Week Range0.84-0.92
MA (50)1.069672
MA (200)1.780035
Market Cap8.18 Mil.
Shares Out.9.25 Mil.
Earnings DateMay 10, 2022
Beta
Last Dividend
EPS
PE

Industry Competitors for PROG

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us